MedElevator
Войти в исследования Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: 'Auckland Classification' v1.0.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Varghese Chris, Dachs Nicky, Schamberg Gabriel, Abell Thomas, Al-Haddad Mohammad, Angeli-Gordon Timothy Robert, Ayazi Shahin, Ayubi Homira, Bashashati Mohammad, Bulat Robert, Calder Stefan, Cederwall Christopher Brian, Chang Bianca, Cheng Leo, Clarke John, Daker Charlotte, Du Peng, Erickson Jon, Eriksson Sven, Fikree Asma, Foong Daphne, Fox Mark, Ghoshal Uday Chand, Goenka Mahesh, Haidry Rehan, Hasler William L, Hayee Bu'Hussain, Ho Vincent, Holtman Gerald, Hobson Anthony Robert, Huang I-Hsuan, Keszthelyi Daniel, Khalsa Sahib S, Koloski Natasha, Kuo Braden, Kunkel David, Law Mikaela, Levinthal David, Liu Joy J, Mathur Prateek, Moshiree Baharak, Neshatian Leila, Ngo Catherine, Nguyen Linda, Oblizajek Nicholas R, Parkman Henry P, Pandanaboyana Sanjay, Podboy Alexander, Rezaie Ali, Sharma Amol, Simmonds Sam, Sivakumar Jonathan, Sirimongkolkasem Jarongkorn, Sonu Irene, Stocker Abigail, Sujka Joseph, Tack Jan, Verdonk Charles, Wang Xiao Jing, Weinstein Douglas, Windsor John, Wongjarupong Nicha, Xu William, Zarate-Lopez Natalia, Andrews Christopher N, Gharibans Armen A, O'Grady Greg
Аннотация
METHODS: A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement.
RESULTS: Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut-brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism-based treatment guidelines. Ten out of the eleven statements had > 80% agreement.
CONCLUSIONS: The Auckland Classification, derived by international consensus, presents a structured framework for BSGM-defined patient phenotypes. Evidence and mechanism-based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.